Compare PDX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | QURE |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | NY | Netherlands |
| Employees | N/A | 248 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.4M | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | PDX | QURE |
|---|---|---|
| Price | $20.47 | $17.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.92 |
| AVG Volume (30 Days) | 140.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.47 | $8.73 |
| 52 Week High | $25.25 | $71.50 |
| Indicator | PDX | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 53.07 |
| Support Level | $19.95 | $13.47 |
| Resistance Level | $22.29 | $18.37 |
| Average True Range (ATR) | 0.45 | 1.33 |
| MACD | -0.15 | 0.27 |
| Stochastic Oscillator | 3.39 | 87.86 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.